Sun Pharma partners with ICGEB to develop dengue vaccine
pharmafile | October 19, 2016 | News story | Research and Development | Vaccine, dengue, icgeb, sun pharmaceutical
Indian drug firm Sun Pharma is set to join forces with the International Centre for Generic Engineering and Biotechnology (ICGEB) to develop a vaccine to tackle dengue and all four of its serotypes.
As part of the partnership, Sun Pharma will have exclusive global rights for the development and commercialisation of the vaccine candidate, and will provide support and funding to further the progress of ICGEB research and patents which include “a tailored recombinant virus-like particle (VLP) based tetravalent dengue vaccine”.
ICGEB has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this dengue vaccine candidate,” Sun Pharma commented. According to the company, the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns. “These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programmes that are developed or in development globally. This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population,” the firm added.
On the other end of the agreement, ICGEB will disclose all pertinent research data in exchange for royalty and milestone payments for sales of the vaccine. The project will be overseen by a joint development committee formed from members of both organisations.
The pair previously announced a dengue-related collaboration in May 2016, focusing on a botanical drug treatment of the virus.
Matt Fellows
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
After completing a safety review of Ixchiq – a vaccine for chikungunya – the European …
